# EDGAR Filing Document

**Accession Number:** 0000920148
**File Stem:** 0000920148-26-000019
**Filing Date:** 2026-2
**Character Count:** 11241
**Document Hash:** 369aa782bebc529b24a481d62cc64b3d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000920148-26-000019.hdr.sgml**: 20260209

**ACCESSION NUMBER**: 0000920148-26-000019

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260206

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260209

**DATE AS OF CHANGE**: 20260209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LABCORP HOLDINGS INC.
- **CENTRAL INDEX KEY:** 0000920148
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 992588107
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11353
- **FILM NUMBER:** 26609731

**BUSINESS ADDRESS:**
- **STREET 1:** 358 S MAIN ST
- **CITY:** BURLINGTON
- **STATE:** NC
- **ZIP:** 27215
- **BUSINESS PHONE:** 3362291127

**MAIL ADDRESS:**
- **STREET 1:** 358 S MAIN ST
- **CITY:** BURLINGTON
- **STATE:** NC
- **ZIP:** 27215

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LABORATORY CORP OF AMERICA HOLDINGS
- **DATE OF NAME CHANGE:** 19950504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NATIONAL HEALTH LABORATORIES HOLDINGS INC
- **DATE OF NAME CHANGE:** 19940314

?xml version='1.0' encoding='ASCII'? lh-20260206

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

<u>February 6, 2026</u>

(Date of earliest event reported)

**LABCORP HOLDINGS INC.** 

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-11353** | **99-2588107** |
| (State or other jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

---

| | | | |
|:---|:---|:---|:---|
| **358 South Main Street** | **358 South Main Street** | **358 South Main Street** | |
| **Burlington** | **,** | **North Carolina** | **27215** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) | (Zip Code) |

---

(Registrant's telephone number including area code) **336-229-1127** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of exchange on which registered** |
| Common Stock, $0.10 par value | LH | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

------

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |
| Labcorp Holdings Inc. (the "Company") today announced that on February 6, 2026, the Company's Board of Directors (the "Board") appointed John H. Sampson, M.D., Ph.D., as a member of the Board, effective February 9, 2026. In connection with Dr. Sampson's appointment, the Board has appointed Dr. Sampson to the Quality and Compliance Committee. Dr. Sampson will be entitled to receive compensation for his service on the Board consistent with the Company's director compensation program, as described in the Company's most recent proxy statement, filed with the Securities and Exchange Commission on April 4, 2025.<br>Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. Before joining the CU Anschutz School of Medicine, Dr. Sampson held senior leadership roles at Duke University Health System, where he served as senior vice president and led the Duke Health Integrated Practice. He is a practicing neurosurgeon, a member of the National Academy of Medicine, and has authored nearly 300 peer-reviewed publications, with a long track record of research focused on advancing new therapies for neurologic disease. | Labcorp Holdings Inc. (the "Company") today announced that on February 6, 2026, the Company's Board of Directors (the "Board") appointed John H. Sampson, M.D., Ph.D., as a member of the Board, effective February 9, 2026. In connection with Dr. Sampson's appointment, the Board has appointed Dr. Sampson to the Quality and Compliance Committee. Dr. Sampson will be entitled to receive compensation for his service on the Board consistent with the Company's director compensation program, as described in the Company's most recent proxy statement, filed with the Securities and Exchange Commission on April 4, 2025.<br>Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. Before joining the CU Anschutz School of Medicine, Dr. Sampson held senior leadership roles at Duke University Health System, where he served as senior vice president and led the Duke Health Integrated Practice. He is a practicing neurosurgeon, a member of the National Academy of Medicine, and has authored nearly 300 peer-reviewed publications, with a long track record of research focused on advancing new therapies for neurologic disease. |
| **Item 7.01** | **Regulation FD Disclosure.** |
| On February 9, 2026, the Company issued a press release announcing the appointment of Dr. Sampson to the Board. A copy of that press release is attached to, and incorporated by reference into, this current report as Exhibit 99.1. | On February 9, 2026, the Company issued a press release announcing the appointment of Dr. Sampson to the Board. A copy of that press release is attached to, and incorporated by reference into, this current report as Exhibit 99.1. |

---

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |
| <u>Exhibit</u> | <u>Exhibit Name</u> |
| Exhibit 99.1 | <u>[Press Release dated](formpr020926ex991boardmemb.htm)[February](formpr020926ex991boardmemb.htm)[9](formpr020926ex991boardmemb.htm)[, 202](formpr020926ex991boardmemb.htm)[6](formpr020926ex991boardmemb.htm)[issued by the Company](formpr020926ex991boardmemb.htm)</u> |
| Exhibit 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>LABCORP HOLDINGS INC.</u>

Registrant

---

| | | |
|:---|:---|:---|
| Date: February 9, 2026 | By: | /s/ KATHRYN W. KYLE |
|  |  | Kathryn W. Kyle |
|  |  | Executive Vice President, Chief Legal Officer and Corporate Secretary |

---

## Exhibit 99.1

![lc2020logov2.gif](lc2020logov2.gif)

**<u>FOR IMMEDIATE RELEASE</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

---

| | |
|:---|:---|
| **Neil Hirsch - Media** | **Christin O'Donnell - Investors** |
| Media@Labcorp.com&nbsp;&nbsp;&nbsp;&nbsp; | Investor@Labcorp.com |

---

**Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors**

**BURLINGTON, N.C., (February 9, 2026)** — Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026.

Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical research, medical education and large-scale health system leadership. He also has deep expertise in oncology, neuroscience, women's health and personalized medicine which aligns with Labcorp's strategic areas of focus.

"John is widely respected as a leader in academic medicine, clinical practice, health system strategy and research," said Adam Schechter, Chairman and Chief Executive Officer of Labcorp. "His expertise will help advance Labcorp's strategy across diagnostics and drug development and enhance the value we deliver to customers."

Before joining the CU Anschutz School of Medicine, Dr. Sampson held senior leadership roles at Duke University Health System, where he served as senior vice president and led the Duke Health Integrated Practice. He is a practicing neurosurgeon, a member of the National Academy of Medicine, and has authored nearly 300 peer-reviewed publications, with a long track record of research focused on advancing new therapies for neurologic disease.

"Labcorp plays a critical role in advancing earlier diagnosis, personalized medicine and the development of new therapies," said Dr. Sampson. "I look forward to contributing my clinical and research experience to help further the company's mission of improving health and improving lives."

In connection with Dr. Sampson's appointment, the Board has appointed Dr. Sampson to the Quality and Compliance Committee.

**About Labcorp**

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.